The Research Institute of the McGill University Health Centre, Division of Pediatric Allergy Immunology and Dermatology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.
EpiVax, Inc., Providence, RI, United States.
Front Immunol. 2021 Apr 19;12:634509. doi: 10.3389/fimmu.2021.634509. eCollection 2021.
Tregitopes (T regulatory epitopes) are IgG-derived peptides with high affinity to major histocompatibility complex class II (MHCII), that are known to promote tolerance by activating T regulatory cell (Treg) activity. Here we characterized the effect of IgG Tregitopes in a well-established murine model of allergic asthma, demonstrating antigen-specific tolerance adoptive transfer of Tregitope-and-allergen-activated Tregs. Asthma is a heterogeneous chronic inflammatory condition affecting the airways and impacting over 300 million individuals worldwide. Treatment is suppressive, and no current therapy addresses immune regulation in severely affected asthmatics. Although high dose intra-venous immunoglobulin (IVIg) is not commonly used in the asthma clinic setting, it has been shown to improve severe asthma in children and in adults. In our laboratory, we previously demonstrated that IVIg abrogates airway hyperresponsiveness (AHR) in a murine model of asthma and induces suppressive antigen-specific T-regulatory cells. We hypothesized that IgG-derived Tregitopes would modulate allergic airway disease by inducing highly suppressive antigen-specific Tregs capable of diminishing T effector cell responses and establishing antigen-specific tolerance. Using ovalbumin (OVA-) and ragweed-driven murine models of allergic airway disease, we characterized the immunoregulatory properties of Tregitopes and performed Treg adoptive transfer to OVA- and ragweed-allergic mice to test for allergen specificity. Treatment with Tregitopes attenuated allergen-induced airway hyperresponsiveness and lung inflammation. We demonstrated that Tregitopes induce highly suppressive allergen-specific Tregs. The tolerogenic action of IgG Tregitopes in our model is very similar to that of IVIg, so we foresee that IgG Tregitopes could potentially replace steroid-based treatment and can offer a synthetic alternative to IVIg in a range of inflammatory and allergic conditions.
Tregitopes(调节性表位)是与主要组织相容性复合体 II(MHCII)具有高亲和力的 IgG 衍生肽,已知通过激活调节性 T 细胞(Treg)活性来促进耐受性。在这里,我们在已建立的变应性哮喘小鼠模型中研究了 IgG Tregitopes 的作用,证明了抗原特异性耐受通过抗原特异性 Tregitope 和过敏原激活的 Tregs 的过继转移。哮喘是一种影响气道的异质性慢性炎症性疾病,影响全球超过 3 亿人。治疗是抑制性的,目前没有治疗方法可以解决严重哮喘患者的免疫调节问题。尽管大剂量静脉注射免疫球蛋白(IVIg)在哮喘临床环境中不常用,但已证明它可以改善儿童和成人的严重哮喘。在我们的实验室中,我们之前证明 IVIg 可消除哮喘小鼠模型中的气道高反应性(AHR),并诱导具有抑制性的抗原特异性 T 调节细胞。我们假设 IgG 衍生的 Tregitopes 通过诱导能够减少 T 效应细胞反应并建立抗原特异性耐受的高度抑制性抗原特异性 Tregs 来调节变应性气道疾病。使用卵清蛋白(OVA)和豚草驱动的变应性气道疾病小鼠模型,我们研究了 Tregitopes 的免疫调节特性,并进行了 Treg 过继转移到 OVA 和豚草过敏小鼠中,以测试抗原特异性。Tregitopes 治疗可减轻过敏原诱导的气道高反应性和肺部炎症。我们证明 Tregitopes 诱导高度抑制性的抗原特异性 Tregs。在我们的模型中,IgG Tregitopes 的耐受性作用与 IVIg 非常相似,因此我们预计 IgG Tregitopes 可能替代基于类固醇的治疗,并为一系列炎症和过敏条件提供 IVIg 的合成替代。